James McDonough
Psychiatry · Longwood, FLNPI 1063468700
Payments from drug & device makers
Across 240 payments — averaging $650.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$151K
- Johnson & Johnson$653
- Otsuka America Pharmaceutical, Inc.$501
- AbbVie$393
- Supernus Pharmaceuticals, Inc.$371
- Neurocrine Biosciences, Inc.$360
- plus $3K from 24 others
What the payments were for
- Food & beverage$4,74799%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 4 | $151,252 |
| Johnson & Johnson | 32 | $653 |
| Otsuka America Pharmaceutical, Inc. | 28 | $501 |
| AbbVie(2 entities) | 21 | $393 |
| Supernus Pharmaceuticals, Inc. | 6 | $371 |
| Neurocrine Biosciences, Inc. | 14 | $360 |
| Lundbeck LLC | 17 | $341 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $320 |
| Corium, LLC | 13 | $217 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $215 |
| Tris Pharma Inc | 12 | $198 |
| Vanda Pharmaceuticals Inc. | 8 | $171 |
| Axsome Therapeutics, Inc. | 6 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $114 |
| Sunovion Pharmaceuticals Inc. | 5 | $92 |
| Almatica Pharma LLC | 4 | $83 |
| Idorsia Pharmaceuticals US Inc | 5 | $73 |
| Alkermes, Inc. | 3 | $68 |
| Merck | 4 | $64 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Neuronetics, Inc. | 4 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Validus Pharmaceuticals LLC | 2 | $52 |
| Ironshore Pharmaceuticals Inc. | 3 | $48 |
| Shire North American Group Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Neos Therapeutics, LP | 2 | $29 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$293
How this compares
$156,034 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 117 | $137,939 |
| VraylarCariprazine Hcl | 42 | $70,363 |
| Invega SustennaPaliperidone Palmitate | 13 | $49,010 |
| RexultiBrexpiprazole | 25 | $39,543 |
| TrintellixVortioxetine Hydrobromide | 17 | $14,700 |
| VyvanseLisdexamfetamine Dimesylate | 27 | $13,977 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 220 | $7,896 |
| Duloxetine Hcl | 466 | $7,386 |
| Lisdexamfetamine Dimesylate | 31 | $7,267 |
| Aripiprazole | 120 | $6,956 |
| Bupropion XlBupropion Hcl | 300 | $6,272 |
| Quetiapine Fumarate | 202 | $4,408 |
| Ziprasidone Hcl | 53 | $4,008 |
| Alprazolam | 616 | $3,985 |
| Clonazepam | 337 | $3,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $653 | $186,949130 claims |
| AbbVieVraylar | $393 | $70,36342 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $501 | $39,54325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $320 | $28,67744 claims |
| Almatica Pharma LLCSertraline Hcl | $83 | $1,032108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Longwood
- Robert MolpusLongwood$5.5M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.